Abbott and Pharmacosmos A/S Sign Agreement to License and Develop Next Generation Intravenous Iron Product for Dialysis
Abbott Laboratories and Pharmacosmos A/S today announced the signing of a license and development agreement for a next generation intravenous iron product. Injectable pharmaceutical iron products are used for the treatment of iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving erythropoietin therapy.
Under terms of the agreement, Abbott has an exclusive license to develop, market and sell the advanced iron therapy in the United States. Pharmacosmos has retained the development and commercial rights outside the United States. Financial terms of the agreement and product details were not disclosed.
"This collaboration provides Abbott with a great opportunity to expand our offering of renal care products and provide hemodialysis patients with more clinical options," said Christopher Begley, senior vice president, hospital products, Abbott Laboratories.
"We are very pleased to reach this agreement with Abbott, which is one of the most powerful and dedicated marketing organizations within the hospital environment in the world," said Lars Christensen, M.D., president, Pharmacosmos. "Pharmacosmos' new injectable iron is a promising new drug, which in clinical use, could exhibit properties that will serve yet unmet clinical needs."
Other news from the department
